Sientra (NASDAQ: INGN) and Inogen (NASDAQ:INGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sientra and Inogen, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sientra 0 0 9 0 3.00
Inogen 0 1 5 0 2.83

Sientra currently has a consensus price target of $24.14, indicating a potential downside of 4.57%. Inogen has a consensus price target of $238.80, indicating a potential downside of 14.12%. Given Sientra’s stronger consensus rating and higher probable upside, research analysts plainly believe Sientra is more favorable than Inogen.

Insider & Institutional Ownership

89.2% of Sientra shares are held by institutional investors. Comparatively, 96.5% of Inogen shares are held by institutional investors. 31.0% of Sientra shares are held by insiders. Comparatively, 5.3% of Inogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Sientra has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sientra and Inogen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sientra $36.54 million 19.68 -$64.02 million ($2.82) -8.97
Inogen $249.44 million 23.80 $21.00 million $1.31 212.27

Inogen has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.


This table compares Sientra and Inogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sientra -131.16% -151.47% -58.22%
Inogen 10.39% 16.51% 13.48%


Inogen beats Sientra on 10 of the 14 factors compared between the two stocks.

Sientra Company Profile

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

Inogen Company Profile

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with's FREE daily email newsletter.